Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Polybrominated Diphenyl Ethers (PBDEs) and Human Health: Effects on Metabolism, Diabetes and Cancer.
Renzelli V, Gallo M, Morviducci L, Marino G, Ragni A, Tuveri E, Faggiano A, Mazzilli R, Natalicchio A, Zatelli MC, Montagnani M, Fogli S, Giuffrida D, Argentiero A, Danesi R, D'Oronzo S, Gori S, Franchina T, Russo A, Monami M, Sciacca L, Cinieri S, Colao A, Avogaro A, Di Cianni G, Giorgino F, Silvestris N. Renzelli V, et al. Among authors: danesi r. Cancers (Basel). 2023 Aug 24;15(17):4237. doi: 10.3390/cancers15174237. Cancers (Basel). 2023. PMID: 37686512 Free PMC article. Review.
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.
Silvestris N, Del Re M, Azzariti A, Maiello E, Lombardi L, Cinieri S, Guarini A, Brunetti AE, Delcuratolo S, De Vita F, Pisconti S, Danesi R, Colucci G. Silvestris N, et al. Among authors: danesi r. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S111-7. doi: 10.1517/14728222.2011.652089. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22443211 Review.
Clinical pharmacology of intravitreal anti-VEGF drugs.
Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Fogli S, et al. Among authors: danesi r. Eye (Lond). 2018 Jun;32(6):1010-1020. doi: 10.1038/s41433-018-0021-7. Epub 2018 Feb 5. Eye (Lond). 2018. PMID: 29398697 Free PMC article. Review.
Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Di Maio M, Petrini I, Danesi R. Del Re M, et al. Among authors: danesi r. Oncotarget. 2017 Dec 21;9(5):6630-6643. doi: 10.18632/oncotarget.23553. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464099 Free PMC article. Review.
517 results